Immutable audit ledger
Every regulated event signed with HSM-backed ECDSA P-384, hash-chained on Hyperledger Fabric, anchored daily to Polygon. Tamper-evident within fifteen minutes.
21 CFR Part 11
Certified. Permanent. Trusted.
Laboratory data goes in. A signed, hash-chained submission comes out, ready for the FDA and the FTC. Each document is its own token, with its own key and its own access-control list.
Token 1271.320 · labelling claims
CERTIFIEDAudit trail
09:14 TOKEN_CERTIFIED · a.reyes
08:56 TOKEN_VERIFIED · 0.98
17:02 OBSERVER_READ · did:fda:cber
The platform
No raw content on the blockchain. No accent colors competing for attention. No marketing language where precision is required. The platform is built for the audit you hope never comes, and the one you know eventually will.
Every regulated event signed with HSM-backed ECDSA P-384, hash-chained on Hyperledger Fabric, anchored daily to Polygon. Tamper-evident within fifteen minutes.
21 CFR Part 11
Seven-stage pipeline: schema validation, anomaly detection, cross-test consistency, completeness scoring, regulatory mapping, FTC claim analysis, confidence scoring.
Auto-VERIFIED ≥ 0.95
FDA mandatory and FTC conditional routing in one submission. CDISC SDTM / ADaM and FTC § 5 / Endorsement Guides validated in a single workflow.
16 CFR 255 · 21 CFR 820
FDA and FTC representatives query ledger state directly via decentralized identity. Every read is itself audited. No export packages, no email-and-PDF discovery.
Audit Channel · read-only
GCP Assured Workloads in us-east4 with us-central1 disaster recovery. Chronicle SIEM. Cloud HSM key custody. NIST SP 800-53 Rev 5 High baseline.
421 controls
Each regulated document is its own cryptographic token with its own ACL. No raw content on the blockchain. Rejection affects only the failed token, never the whole application.
AES-256-GCM CMEK
The workflow
A single workflow from raw laboratory data through anchored federal submission. Every step is permanent. Every step is provable.
Create a product token in the ledger. Select CFR scope: 21 CFR 211 (drug), 820 (device), 1271 (HCT/P), 42 CFR 493 (CLIA), 16 CFR (FTC).
Lab instruments push data through the LabData chaincode handshake. CDISC SDTM, ADaM, COA, and IRT validated on ingest. Schema failures never reach the ledger.
The seven-stage pipeline scores every submission. Confidence ≥ 0.95 auto-VERIFIED. Lower scores route to human review with the specific CFR clause cited.
Authorized signatory ceremony locks the manifest into the AUTHORIZED state. Submission flows to FDA / FTC. The manifest hash anchors to Polygon for permanent verifiability.
Trust architecture
Trust is the product. The platform is designed so that every record is permanent, every key is hardware-protected, every access is audited, and every claim is independently verifiable.
FedRAMP High · NIST SP 800-53 Rev 5
AES-256-GCM CMEK · Cloud HSM
Polygon · 15-minute Merkle root
Observer DID · Audit Channel
Access tiers
Mutaris serves single-person startups and global pharmaceutical enterprises from one platform. Pricing is finalized per engagement. The tier model below describes the submission shape.
Small business
Independent labs, startups, single-product companies. Submit one subsection at a time. Same compliance guarantee as the enterprise tier.
Submission model
Pay-per-subsection
Mid-sized company
Regional device and pharma companies with dedicated regulatory teams. Section-by-section submission with predictable billing tied to functional milestones.
Submission model
Section-level
Enterprise
Large pharma, biotech, and medical device companies with mature regulatory operations. FedRAMP High and HIPAA are table stakes. Full-document submission with multi-party authorization.
Submission model
Full-document atomic
Regulatory Agency users (FDA, FTC, CMS) and platform staff use a separate access tier with no business-data read. The platform spec defines the full user-class model.
Pilot · Tier 1 onboarding open
Mutaris is onboarding regulated teams ahead of the FedRAMP ATO. If your organization submits to the FDA or FTC, we want to talk.